MBCProject_1334_T2_RNA
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.490
- INFLAMMATORY_RESPONSE+0.450
- INTERFERON_GAMMA_RESPONSE+0.440
- ANGIOGENESIS+0.420
- ALLOGRAFT_REJECTION+0.410
- E2F_TARGETS+0.400
- INTERFERON_ALPHA_RESPONSE+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.360
- PANCREAS_BETA_CELLS+0.360
- TNFA_SIGNALING_VIA_NFKB+0.360
Top 10 suppressed
- NOTCH_SIGNALING-0.410
- ESTROGEN_RESPONSE_EARLY-0.240
- WNT_BETA_CATENIN_SIGNALING-0.180
- APICAL_SURFACE-0.160
- BILE_ACID_METABOLISM-0.150
- MYOGENESIS-0.130
- PEROXISOME-0.130
- APICAL_JUNCTION-0.090
- P53_PATHWAY-0.090
- HEME_METABOLISM-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_1170_T1_RNA | — | D | 0.913 |
| 2 | DRR168574 | — | — | 0.891 |
| 3 | MNG380 | — | — | 0.890 |
| 4 | SRR8518252 | — | A | 0.846 |
| 5 | SRR29022839 | — | A | 0.843 |
| 6 | SJEPD030791_D1.RNA-Seq | EPN | Supratentorial EPN | 0.841 |
| 7 | TCGA-BT-A20X-01A-11R-A16R-07 | — | — | 0.837 |
| 8 | MNG742 | — | — | 0.836 |
| 9 | SRR1516056 | — | — | 0.836 |
| 10 | TCGA-DK-A3WW-01A-22R-A23N-07 | — | — | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.450 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.360 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.310 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.270 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| HYPOXIA | 0.240 | Idelalisib | — uncovered |